Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -200% Improvement Relative Risk ICU admission 67% Hospitalization time 10% HCQ for COVID-19  Uyaroğlu et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM retrospective 84 patients in Turkey (March - September 2020) Study compares with favipiravir, results vs. placebo may differ Study underpowered for serious outcomes c19hcq.org Uyaroğlu et al., Acta Medica, March 2022 Favors HCQ Favors favipiravir

Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study

Uyaroğlu et al., Acta Medica, doi:10.32552/2022.ActaMedica.719
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
PSM retrospective 260 late stage hospitalized COVID-19 pneumonia patients in Turkey, showing no significant difference between favipiravir and HCQ.
Study covers HCQ and favipiravir.
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 42 (2.4%), control 0 of 42 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 42 (0.0%), control 1 of 42 (2.4%), NNT 42, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 9.8% lower, relative time 0.90, p = 0.90, treatment 42, control 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Uyaroğlu et al., 17 Mar 2022, retrospective, propensity score matching, Turkey, peer-reviewed, 6 authors, study period 20 March, 2020 - 30 September, 2020, this trial compares with another treatment - results may be better when compared to placebo. Contact: oguzuyaroglu@hotmail.com.
This PaperHCQAll
Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Singlecenter, Retrospective, Propensity Score-matched Study
Oğuz Abdullah Uyaroğlu
In this study, we compared the clinical outcomes and effects of the treatments on laboratory parameters between patients who were treated with favipiravir (FAV) or hydroxychloroquine plus azithromycin (HCQ/AZ) for COVID-19 pneumonia in non-Intensive Care Unit (non-ICU) patients. Methods: We collected data of 260 moderate or severe COVID-19 patients hospitalized in COVID-19 wards between March 20, 2020, and September 30, 2020 retrospectively. We used propensity score matching to evaluate treatment effect on laboratory parameters of COVID-19 infection. Results: We compared 42 patients using FAV and 42 HCQ/AZ after propensity score matching. While there were statistical differences between the therapy groups in terms of transfer to ICU and/or exitus before matching (p=0.031), this was not significant after propensity analysis (p=0.250). Patients treated with FAV stayed in the hospital nearly one more day than HCQ/AZ group but the difference was not statistically significant (9.02 days vs 8.14 days, p=0.903). The levels of AST,ALT, and LDH increased at discharge in both groups, especially in the FAV group. Conclusions: FAV is not superior to HCQ/AZ in the treatment of COVID-19 infection in hospitalized patients with pneumonia.
Author contribution Study conception and design: ÖU, OAU, and NÇB; data collection: OAU, MÇS, and GTD; analysis and interpretation of results: OAU, MÇS, GTD, NÇB, SK, ÖU; draft manuscript preparation OAU, and ÖU. All authors reviewed the results and approved the final version of the manuscript. Ethical approval The study was approved by the Hacettepe University Non-interventional Clinical Research Ethics Board (Protocol no. GO 20/353/31/03/2020). Funding The authors declare that the study received no funding. Conflict of interest The authors declare that there is no conflict of interest.
References
Bouazza, Treluyer, Foissac, Favipiravir for children with Ebola, Lancet
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering
Chen, Zhang, Huang, Favipiravir versus arbidol for COVID-19: a randomized clinical trial
Dabbous, Abd-Elsalam, El-Sayed, Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Archives of Virology
Dabbous, El-Sayed, Assal, Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial, Scientific Reports
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrobial agents and chemotherapy
Doi, Ikeda, Hayase, Nafa mostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series, Crital Care
Fu, Cao, Zhao, Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series, Crital Care
Furuta, Gowen, Takahashi, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Research
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International journal of antimicrobial agents
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, New England Journal of Medicine
Inkaya, Kara, Başaran, Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients, Turk J Med Sci
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a pha se II/III multicenter randomized clinical trial, Clinical Infectious Disease
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, International Journal of Infectious Diseases
Kocayiğit, Süner, Tomak, Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19, Journal of Clinical Pharmacy and Therapeutics
Li, Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nature Reviews Drug Discovery
Lou, Liu, Yao, Clinical outcomes and plasma concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 patients: An exploratory randomized, controlled trial, European Journal of Pharmaceutical Sciences
Piszczatoski, Powell, Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19, Annals of Pharmacotherapy
Recovery Collaborative, Effect of hydroxychloroquine in hospitalized patients with Covid-19, New England Journal of Medicine
Simmering, Polgreen, Polgreen, Teske, Comellas et al., The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin, Pharmacotherapy, doi:10.1002/phar.2445
Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Victoria, Pepperrell, Hill, A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?, Journal of virus eradication
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Research
Yamamura, Matsuura, Nakagawa, Effect of favipiravir and an anti-inflammatory strategy for COVID-19, Critical Care
Yuki, Sadako, Kazuhiro, Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir, Diagn. Microbiol. Infect. Dis
Çalık Başaran, Uyaroğlu, Dizman, Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU, Turk J Med Sci
Çilingir, Sunnetcioglu, Yildiz, What Is The Case of More Accessible Treatment Options in COVID 19: Comparison of Hydroxychloroquine and Favipiravir Based on Laboratory Values, Eastern Journal of Medicine
Özlüşen, Kozan, Akcan, Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis
{ 'DOI': '10.32552/2022.actamedica.719', 'ISSN': ['2147-9488'], 'URL': 'http://dx.doi.org/10.32552/2022.ActaMedica.719', 'abstract': '<jats:p>Objectives: In this study, we compared the clinical outcomes and effects of the ' 'treatments on laboratory parameters between patients who were treated with favipiravir (FAV) ' 'or hydroxychloroquine plus azithromycin (HCQ/AZ) for COVID-19 pneumonia in non-Intensive Care ' 'Unit (non-ICU) patients.&#x0D;\n' 'Methods: We collected data of 260 moderate or severe COVID-19 patients hospitalized in ' 'COVID-19 wards between March 20, 2020, and September 30, 2020 retrospectively. We used ' 'propensity score matching to evaluate treatment effect on laboratory parameters of COVID-19 ' 'infection.&#x0D;\n' 'Results: We compared 42 patients using FAV and 42 HCQ/AZ after propensity score matching. ' 'While there were statistical differences between the therapy groups in terms of transfer to ' 'ICU and/or exitus before matching (p=0.031), this was not significant after propensity ' 'analysis (p=0.250). Patients treated with FAV stayed in the hospital nearly one more day than ' 'HCQ/AZ group but the difference was not statistically significant (9.02 days vs 8.14 days, ' 'p=0.903). The levels of AST,ALT, and LDH increased at discharge in both groups, especially in ' 'the FAV group.&#x0D;\n' 'Conclusions: FAV is not superior to HCQ/AZ in the treatment of COVID-19 infection in ' 'hospitalized patients with pneumonia.</jats:p>', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-0440-2026', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Uyaroğlu', 'given': 'Oğuz Abdullah', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0001-6529-5282', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Sönmezer', 'given': 'Meliha Çağla', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0001-8195-3345', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Telli Dizman', 'given': 'Gülçin', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0002-1290-6905', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Çalık Başaran', 'given': 'Nursel', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0002-8692-7266', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Karahan', 'given': 'Sevilay', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0003-4721-0139', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Uzun', 'given': 'Ömrüm', 'sequence': 'first'}], 'container-title': 'Acta Medica', 'container-title-short': 'Acta Medica', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 3, 26]], 'date-time': '2022-03-26T13:55:42Z', 'timestamp': 1648302942000}, 'deposited': { 'date-parts': [[2022, 3, 26]], 'date-time': '2022-03-26T13:55:47Z', 'timestamp': 1648302947000}, 'indexed': {'date-parts': [[2022, 4, 1]], 'date-time': '2022-04-01T05:03:31Z', 'timestamp': 1648789411476}, 'is-referenced-by-count': 0, 'issue': '1', 'issued': {'date-parts': [[2022, 3, 17]]}, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 3, 26]]}}, 'license': [ { 'URL': 'http://creativecommons.org/licenses/by/4.0', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 3, 17]], 'date-time': '2022-03-17T00:00:00Z', 'timestamp': 1647475200000}}], 'link': [ { 'URL': 'https://actamedica.org/index.php/actamedica/article/download/719/558', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://actamedica.org/index.php/actamedica/article/download/719/558', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '17016', 'original-title': [], 'page': '73-82', 'prefix': '10.32552', 'published': {'date-parts': [[2022, 3, 17]]}, 'published-online': {'date-parts': [[2022, 3, 17]]}, 'publisher': 'Hacettepe University - Medical School', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://actamedica.org/index.php/actamedica/article/view/719'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'title': 'Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients ' 'with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study', 'type': 'journal-article', 'volume': '53'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit